IRIDEX Major Event this Saturday

Posted on November 4, 2021 by Scott Shuda

For the last several years, IRIDEX Corporation (IRIX), an ophthalmic medical technology company offering treatment solutions for retinal and glaucoma conditions, has been working with physicians to establish optimal treatment parameters relating to its MicroPulse transscleral laser therapy (TLT) for glaucoma.

This Saturday, an international consensus panel of ten glaucoma experts will discuss MicroPulse Transscleral Laser Therapy and their recommendations for dosing and patient selection. The panel executed a complete analysis of the clinical, technical, and practical experience to date and has stepped forward to create a consensus document with recommendations for the worldwide clinical application of MicroPulse TLT. The live webinar will be on Saturday, November 6th at 10:00am Pacific Time (UTC -7), and sixteen crucial questions will be answered during the discussion. The panel will help physicians to better understand the concept of fluence and the importance of sweep speed, and to identify the clinical drivers for patient selection, outcomes, and safety.

IRIX is a company discussed on the Breakout Investor Platform (IRIX) in the Breakout Room hosted by Aaron Warwick. His recent article, Iridex: A Clear Vision For Success, was published by Seeking Alpha on May 18, 2021 and has received a total of 48 comments.

According to Finviz, the stock is up more than 388% over the last year. In early March, IRIDEX announced a major global collaboration with Topcon, a leading Japanese eyecare company.

Source: Finviz
Source Finviz`

Disclosure: the author of this post is long IRIDEX and might buy or sell shares at anytime. In addition, the author is currently Chairman of the Board of Directors of IRIDEX Corporation.

5 1 vote
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x